Albumedix Bookshelf Biosimilars & Biobetters - Strategies and Challanges

Biosimilars & Biobetters - Strategies and Challanges

Publication: BioPharm International e-book

Published: June 2018

Author: Darrell Sleep

Link to pdf

Pyblication type: Veltis

 

"The introduction of platform halflife extension fusion technologies such as Fc or albumin fusions lends itself to platform purification processes whereby albumin or the Fc portion of IgG act as a purification tag, thus simplifying the purification processes and reducing development time and production costs.”

CONTACT

Albumedix Ltd.
Castle Court
59 Castle Boulevard
Nottingham
NG7 1FD, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 


 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with more than 80 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

 

Privacy | Cookies

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2019

FOLLOW US